We evaluated the sensitivity of GC patients to irinotecan, 5-fluorouracil, docetaxel, capecitabine, paclitaxel, cisplatin, and oxaliplatin, based on FBLN5 expression levels, and found that the expression levels of FBLN5 affected the drug sensitivity of capecitabine, cisplatin, and oxaliplatin (Supplementary Table S7) (Figure 5A). The gene discussed is FBLN5; the disease is gastric cancer.